HC Wainwright Reiterates Buy Rating on Arrowhead Pharma, Keeps $120 Target
HC Wainwright reiterated its Buy rating and $120 price target on Arrowhead Pharma. The target implies 105.6% upside from the October 14 close of $58.37.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.